-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Background: Immunocompromised patients are at higher risk for severe COVID-19 outcomes
Immunocompromised patients are at higher risk for severe COVID-19 outcomes
Design, setting, and participants: This retrospective cohort study analyzed data from the National COVID-19 Cohort Collaboration (N3C), a partner that developed a secure, central electronic medical record-based Repository that stores COVID-19 clinical data from academic medical centers across the United States
Key outcomes and measures: Vaccination, diagnosis of COVID-19, diagnosis of immune dysfunction (ie, HIV infection, multiple sclerosis, rheumatoid arthritis, solid organ transplantation and bone marrow transplantation), other complications and demographic data passed N3C data enclave access
RESULTS: A total of 664 722 patients were included in the N3C sample
Conclusions and significance: This cohort study found that adequate vaccination was associated with a reduced risk of COVID-19 breakthrough infection, regardless of the patient's immune status
This cohort study found that adequate vaccination was associated with a reduced risk of COVID-19 breakthrough infection, regardless of the patient's immune status
Association Between Immune Dysfunction and COVID-19 Breakthrough Infection After SARS-CoV-2 Vaccination in the US.
JAMA
leaves a message here
